Advancing Kidney Care Through Groundbreaking Research
At Miami Kidney Group, we are proud to lead the way in nephrology research. Our team has conducted multiple clinical trials to advance treatments for kidney disease, anemia, and dialysis care. Discover how our commitment to innovation enhances the future of kidney health.
Explore Our Research Studies
We work hard to advance treatments for kidney disease, anemia, and dialysis, improving care for patients everywhere.
A randomized Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
ANDES Trial
Sponsor: Fibogen
Protocol: FGCL-4592-060 (non-dialysis)
A phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Roxadustat (FG-4592) for the treatment of Anemia in Chronic Kidney Disease Patients not on Dialysis
PRO2TECT - Correction Trial
Sponsor: Akebia
Protocol:AKB-6548-CI-0014 (non-dialysis)
Phase 3, Randomized, open-label, active-controlled study evaluating the efficacy and safety of oral vadadustat for the correction of anemia in subjects with non-dialysis-dependent Chronic Kidney Disease (NDD-CKD).
ASCEND ND (non-dialysis)
Sponsor GSK
Protocol 200808
Title: A phase 3 randomized, open-label (sponsor-blind), activecontrolled, parallel-group, multi-center, event driven study in non-dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of daprodustat compared to darbepoetin alfa.
ASCEND D
Sponsor GSK
Protocol 200807
A phase 3 randomized, open-label (sponsor-blind), active controlled, parallel-group, multi-center, event driven study in dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of daprodustat compared to recombinant human erythropoietin, following a switch from erythropoietin-stimulating agents.
COMPASS Trial
Sponsor: Keryx
Protocol: KRX-0502-402 (non-dialysis)
Title: A phase 4 study of krx-0502 (ferric citrate) dose regimens in subjects with non-dialysis dependent chronic kidney disease and iron deficiency anemia: the compass trial
SIERRAS Trial
Sponsor: Fibogen
Protocol: FGCL-4592-064 (dialysis)
A Phase 3, Open-Label, Randomized, Active-Controlled Study of the Efficacy and Safety of Roxadustat (FG4592) in the Maintenance Treatment of Anemia in End Stage Renal Disease (ESRD) Subjects on Stable Dialysis.
PRO2TECT Conversion Trial
Sponsor Akebia
Protocol : AKB-6548-CI-0015 (non-dialysis)
Title: Phase 3, randomized, open-label, active-controlled study evaluating the efficacy and safety of oral vadadustat for the maintenance treatment of anemia in subjects with non-dialysis-dependent chronic kidney disease (ndd-ckd) (pro2tect - conversion)
Subscribe to our newsletter and get the latest updates on kidney health, expert tips, and news from Miami Kidney Group. Stay connected with insights that can help you take charge of your well-being.
